Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.
辉瑞制药涨超1%，刷新日高至25.53美元，美国食品药品管理局批准其针对罕见的遗传性出血性疾病的第一代疗法。
Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.